XML 85 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Novartis Collaboration and License Agreement (the "Novartis Agreement") - Additional Information (Details) - Novartis
3 Months Ended 12 Months Ended
Mar. 31, 2020
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
research
Novartis Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Proceeds from upfront non-refundable license fee       $ 50,000,000
Revenue recognized from related party   $ 2,000,000 $ 41,800,000  
Receivable from related party transactions   2,000,000 9,300,000  
Contract assets   0 0  
Contract liabilities   0 0  
Novartis Agreement | Achievement of First Patient Dosing Milestone        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue recognized from related party   391,000,000 $ 25,000,000  
Novartis Agreement | Research and Development        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue recognized from related party $ 16,800,000 7,600,000   7,100,000
Novartis Agreement | License Fee        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue recognized from related party       $ 50,000,000
Novartis Agreement | Maximum        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Number of Integrin research targets | research       3
Collaboration and license agreement, integrin research targets amount       $ 416,000,000
Novartis Agreement RD For PLN-1474        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Transaction price of Novartis agreement   20,000,000   19,600,000
Novartis Agreement RD For Integrin Research Targets | Research and Development        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Transaction price of Novartis agreement   $ 13,400,000   $ 13,400,000